Op-Ed: America’s healthcare system isn’t sustainable. What would a better alternative look like?
By Marc Boutin
Virtually no one in America is satisfied with the healthcare status quo. Not doctors. Not hospital executives. Not drug or insurance company leaders. And most certainly not patients.
This nearly universal anger is setting the stage for seismic reforms. Policymakers in both parties are planning ambitious healthcare overhauls.
Rather than waiting for Washington to impose changes from the top down, it’d be far better for patients, providers, insurers, employers, drug companies, and pharmacy benefit managers to work together now — to reimagine, and ultimately redesign, the system with a shared vision.
America boasts the most talented doctors and best hospitals in the world. Our researchers develop the lion’s share of new medicines. And far more of those treatments are available here than in other peer nations, at least in theory.
Yet despite all these advantages, our current healthcare system fails to deliver the outcomes that matter most to families — because it was simply never designed to do so. We often cannot agree on what healthcare should ultimately accomplish, which outcomes matter most, or what tradeoffs we are willing to tolerate.
In the absence of this shared understanding, companies default to prioritizing their own short-term finances — even if that’s not in the long-term interests of patients, families, or society.
For instance, consider the dilemma facing health insurers. Americans frequently bounce from insurer to insurer as they change jobs, move states, retire and enroll in Medicare, or simply select new plans that better fit their needs.
So even when an expensive treatment would clearly improve a patient’s health and prevent future complications, the insurer or employer that shoulders the upfront cost likely will not reap the eventual savings.
Consider the dilemma posed by gene therapies, which target the underlying genetic malfunctions and mutations that cause certain diseases.
In many cases, a one-time dose of these therapies can completely cure a patient’s disease for life — and prevent millions of dollars in spending on hospitalizations and other care down the road. Multiple gene therapies are cost-effective, even with price tags exceeding $1 million.
In all likelihood, insurers that cover these therapies will see only a fraction of the return before patients switch plans. They therefore have a strong incentive to limit access, even when everyone agrees these treatments offer good value over a lifetime.
This behavior makes perfect sense from the perspective of an individual insurer or employer. But it makes no sense for society as a whole.
We need a genuinely market-based system in which providers, drug companies, and insurers can transparently compete for customers on both price and quality.
And that competition cannot happen unless we first adopt new valuation metrics to better understand the full costs and benefits of different treatments and care models — and then redesign payment and insurance rules so that organizations are rewarded, rather than penalized, for investing in patients’ long-term health.
The question is whether stakeholders can set aside their differences, agree on a shared definition of success, and implement reforms that improve patients’ long-term physical, mental, and financial health.
If they cannot, Washington will eventually impose changes from above.
Marc Boutin, J.D., a three-time cancer survivor and caregiver, is president and CEO of IVI and previously served as CEO of the National Health Council, where he led policy initiatives that helped shape national health care reform. This column originally appeared at DCJournal.com
